Literature DB >> 2868743

The physiological and pharmacological role of presynaptic alpha- and beta-adrenoceptors in man.

M J Brown, A D Struthers, J M Burrin, L Di Silvio, D C Brown.   

Abstract

Two studies were performed each in six normal volunteers in order to find evidence of either a physiological or pharmacological role of presynaptic alpha- and presynaptic beta-adrenoceptors in man. In Study 1 subjects received a 60 min infusion of guanfacine 3 mg (alpha 2-adrenoceptor agonist) preceded by either idazoxan (alpha 2-adrenoceptor antagonist) or vehicle. Guanfacine reduced plasma noradrenaline concentration by approximately 30% and this fall was not antagonised by the alpha 2-receptor antagonist. The 30-fold increase in plasma growth hormone, measured as a marker of the central action of guanfacine, was almost completely blocked by idazoxan. A comparison of the drug concentrations of idazoxan and guanfacine, together with their relative affinities for alpha 2-adrenoceptors, suggested that the idazoxan could not block the peripheral actions of guanfacine and that these were responsible for the fall in plasma noradrenaline concentration. In Study 2 adrenaline 0.05 micrograms kg-1 min-1 was infused for 80 min preceded by either idazoxan or vehicle. After vehicle, adrenaline caused no change in plasma noradrenaline concentration whereas it rose approximately 25% after administration of idazoxan. This was probably due to unmasking of presynaptic beta-adrenoceptor stimulation by adrenaline when the opposing inhibitory autoreceptor was blocked.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2868743      PMCID: PMC1400828          DOI: 10.1111/j.1365-2125.1985.tb05124.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  43 in total

1.  Immunoassay of insulin with insulin-antibody precipitate.

Authors:  C N HALES; P J RANDLE
Journal:  Biochem J       Date:  1963-07       Impact factor: 3.857

2.  Centrally acting drugs in antihypertensive therapy.

Authors:  C T Dollery; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

3.  Pharmacological evidence for a functional role of the prejunctional alpha-adrenoreceptor in noradrenergic neurotransmission in the conscious rat.

Authors:  R M Graham; W H Stephenson; W A Pettinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-03       Impact factor: 3.000

4.  Growth hormone and prolactin secretion by dispersed cell cultures of human pituitary adenomas: long term effects of hydrocortisone, estradiol, insulin, 3,5,3'-triiodothyronine and thyroxine.

Authors:  E F Adams; I E Brajkovich; K Mashiter
Journal:  J Clin Endocrinol Metab       Date:  1981-08       Impact factor: 5.958

5.  The role of calcium in the effects of noradrenaline and phenoxybenzamine on adrenergic transmitter release from atria: no support for negative feedback of release.

Authors:  S Kalsner
Journal:  Br J Pharmacol       Date:  1981-06       Impact factor: 8.739

6.  Regulation of norepinephrine release by peripheral alpha 2-receptor stimulation.

Authors:  G A FitzGerald; J Watkins; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

7.  Adrenaline activation of prejunctional beta-adrenoceptors in guinea-pig atria.

Authors:  H Majewski; M W McCulloch; M J Rand; D F Story
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

8.  Limitations of presynaptic adrenoceptor theory: the characteristics of the effects of noradrenaline and phenoxybenzamine on stimulation-induced efflux of [3H]noradrenaline in vas deferens.

Authors:  S Kalsner
Journal:  J Pharmacol Exp Ther       Date:  1980-02       Impact factor: 4.030

9.  The effects of (+)- and (-)-propranolol on 3H-transmitter efflux in guinea-pig atria and the presynaptic beta-adrenoceptor hypothesis.

Authors:  S Kalsner
Journal:  Br J Pharmacol       Date:  1980-11       Impact factor: 8.739

10.  An interaction between prejunctional alpha-adrenoceptors and prejunctional beta-adrenoceptors.

Authors:  H Majewski; M J Rand
Journal:  Eur J Pharmacol       Date:  1981-02-19       Impact factor: 4.432

View more
  8 in total

1.  An evaluation of the alpha-adrenoceptor antagonism produced by SK&F 86466 in healthy normotensive males.

Authors:  R F Schafers; H L Elliott; C A Howie; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

2.  Are blood pressure surges associated with sympathetic stimulation aggravated by beta-adrenoceptor antagonist treatment?

Authors:  C R Kumana
Journal:  Postgrad Med J       Date:  1986-08       Impact factor: 2.401

3.  Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat.

Authors:  J McDaid; J R Docherty
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

4.  Interaction of salbutamol and galanin on both basal and growth hormone releasing hormone-stimulated growth hormone secretion in humans.

Authors:  E Arvat; J Ramunni; L Gianotti; L Di Vito; M Maccario; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

5.  Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine.

Authors:  J H Krystal; C J McDougle; S W Woods; L H Price; G R Heninger; D S Charney
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Baroreceptor function in man following peripheral alpha 1- and alpha 2-adrenoceptor stimulation.

Authors:  A H Deering; J G Riddell; R G Shanks; D W Harron
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers.

Authors:  S Karhuvaara; A Kallio; M Scheinin; M Anttila; J S Salonen; H Scheinin
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

8.  The effects of a peripherally selective alpha 2-adrenoceptor antagonist, MK-467, on the metabolic and cardiovascular response to exercise in healthy man.

Authors:  D G Sciberras; J W Reed; C Elliott; P G Blain; M R Goldberg
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.